Concepedia

Publication | Open Access

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

DOIFull Paper Access

48

Citations

39

References

2015

Year

Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Badros, Peter M. Voorhees, Rachid Baz, Neha Korde, Hui‐Yi Lin, Jin‐Qiu Chen,
Clinical Cancer Research

Abstract

Single-agent AZD6244 was tolerable and had minimal activity in this heavily pretreated population.

References

YearCitations

Page 1